May. 14 at 1:01 PM
$KROS no surprises in the report today but nice to see continued frugality in their approach. The cash reserves are not much changed since December 2025 and elritercept development has been completely handed off to Takeda.
If you are struggling to understand how rinvatercept will impact DMD and ALS, just think about
$SRRK and their success using a GDF8 prodomain Ab, apitegromab, to treat spinal muscular atrophy (SMA), another neuromuscular disease indication with existing approved therapies that target gene expression of SMN1 or upregulate backup gene SMN2 (Spinraza). Activin and GDF modulation will help with these conditions alongside those gene targeted therapies— clearly you’ll do better if you address both sides of the neuromuscular junction.
The thesis with rinvatercept is that their strategy of targeting multiple activin and GDF ligands will be even more potent than just one alone like apitegromab. Apitegromab looks very promising for SMA, and proves that the concept is sound.
